How to overcome technical difficulties in tumor immunotherapy R&D technology?

On December 7 and 8, 2019 BioTianfu Tumor Immunology Industry, Research and Research Integration Innovation Forum & The 20th Annual Conference on Interferon and Cytokines was hosted by Professional Committee of Interferon and Cytokines of Chinese Society for Microbiology and Jiangsu Biological Technology Association, co-organized by CDHT Investment Group Biomedicine Industrial Park Management Co., Ltd. (Tianfu Life Science Park) and Huihuiyaoka in CDHT,

This conference attracted domestic and foreign scholars such as Hou Yunde, Academician of the Chinese Academy Of Engineering, Wei Yuquan, Academician of the Chinese Academy of Sciences, and executives of more than 200 domestic well-known pharmaceutical enterprises to exchange and share ideas on the latest development and future trend of interferon and cytokine related molecules.

The Innovation Forum for University Scientific and Technological Talents and the Transfer and Transformation of Scientific Research Achievements and Supporting Talents Matchmaking Meeting were convened at the same period of this conference, in order to boost the leapfrog development of interferon and cytokine related molecules as well as tumor immune regulation molecules in a multi-dimensional and comprehensive manner.

The scene of the conference

Advances in basic research and technology in the field of tumor immunology have provided profound knowledge and technical reserve for the development of tumor immune drugs and promoted their explosive growth.

During the conference, Academician Hou Yunde (Academician of Chinese Academy of Engineering, Director of Academician Lab of Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, winner of 2017 State Preeminent Science and Technology Award), Academician Wei Yuquan (Academician of Chinese Academy of Sciences, Professor of Sichuan University and doctoral supervisor), Feng Gensheng (Professor of Pathology and Molecular Biology, University of California, San Diego) and Professor Fu Xinyuan (Internationally renowned molecular biomedical and biochemical scholar from West China Hospital of Sichuan University) all shared their research findings in related fields and aroused attention and discussion of guests.

Academician Hou Yunde

Academician Wei Yuquan

In recent years, the State Administration of Food and Drug Administration and other departments have strengthened supervision. Innovative drugs need to undergo structural design, discovery, preclinical research, clinical research and other tests before coming into the market.  For most pharmaceutical companies, how to improve the application rate of new drugs, how to speed up the entry of new drugs into clinical research, etc. are issues to be considered and discussed urgently. At this conference, Dr. Gu Xingchu, Vice President of Preclinical Research Department of Shanghai Medicilon Inc., elaborated the features of protein/antibody drug, pharmacodynamics, pharmacokinetics, safety research strategies, etc. to provide solutions for the breakthrough of R&D of new drugs.

In addition, during the in-depth discussion of biotech drugs, Mr. Rao Chunming, Director of Recombinant Drugs Department of China Institute of Food and Drug Testing, introduced the research basis and related progress of the quality standard of biotechnology drugs in China, mainly focusing on the technical core contents such as quality control standard of recombinant drugs and its analytical methods. In terms of the multi-hundred-billion-market macro-molecular biological drugs, Han Aiming, General Manager of Greater China Region of ProteinSimple Biotech (Shanghai) Co., Ltd. provided innovative solutions on their natural “defects” such as heavy molecular weight and complicated modification.

As the backbone of R&D of domestic drugs, the scientific research institutions and universities also shared information about tumor immunity or interferon. Cui Daxiang, Vice President of Institute of Nano-biomedical Engineering, Shanghai Research Center for Translational Medicine of Shanghai Jiao Tong University, delivered a report entitled Research on Targeting Imaging and Synergistic Tumor Therapy of Immune Cells Labeled with Nanoparticles. Xing Tongjing, Director of Liver Disease Center of Infectious Disease Department, Taizhou Hospital of Zhejiang Province, also delivered a great speech entitled Research Progress of the Application of Interferon in the cure of Chronic Hepatitis B.

The scene of the conference

The biomedical industry has become a new driving force of global economic development. Based on the research on the development advantages and successful experience of the key global biomedical clusters, a batch of domestic biomedical industrial parks emerged. They actively embraced the new era, made innovations for scientific research, formed industrial clusters and promoted integrated development.

The scene of the conference

During the conference, CDHT Biological Industry Bureau promoted the biological industry of this district, and the industrial strength of CDHT and Tianfu Life Science Park attracted considerable attention.

As the main front of Chengdu biomedical industry, CDHT aims to build a modern biological industry system with international competitiveness and regional driving force, and speeds up the construction of industrial ecosystem of “four chains-community-system”.

Since the beginning of this year, CDHT has successively introduced a number of projects such as Fortune Global 500 Gilead Sciences Western Operation Center, Allergan China Pharmaceutical Trade Headquarters as well as Second Chinese Headquarters and Innovation Center of Boston Scientific, IQVIA Western Operation Headquarters. CDHT continues to promote the cultivation of innovative varieties, assisting 3 class 1 biological products to obtain clinical licenses, 27 class 1 new drugs to enter the clinical stage, as well as 9 drugs and 20 medical device varieties to be approved with production documents and registration certificates. In 2019, the main business revenue of pharmaceutical industry in CDHT is expected to reach RMB 24.3 billion, with a year-on-year growth of 18%, and the scale of biological industry will exceed RMB 50 billion for the first time.

CDHT

As the Biomedical Industrial Park with the longest history in CDHT, Tianfu Life Science Park is the biological research, development and innovation center as well as the industry incubation center built in Chengdu. It has attracted over 6000 biomedical employees and introduced 174 domestic and foreign famous enterprises (such as West China Hospital, Hengrui Medicine, ChemPartner and Gooddoctor Pharmaceutical Group) and innovative & entrepreneurial enterprises (such as Conmed Biosciences, Xiling Lab, Antejin Biotechnology and MaxHealth Biotech). Over 400 first-class international and domestic projects have been carried out there, including over 50 Class I new drug projects under research.

Tianfu Life Science Park

“After 10 years of operation and development, many innovative biomedical enterprises have been attracted to this park. Through enterprise interaction, industrial clusters have been formed to lay a solid foundation for the development of bio-industry in CDHT.” Person in charge of the park said. As a cooperative project launched by Sichuan University and CDHT, part of the carriers of Stage II of Tianfu Life Science Park will be built into the Chengdu Advanced Medical Sciences Center will the assistance of Sichuan University. This center aims to build an excellent world-class base of “medicine +” innovation research, project incubation and industry introduction. The first batch of carriers were delivered in September this year.

Stage II of Tianfu Life Science Park